Alteogen Inc
KOSDAQ:196170

Watchlist Manager
Alteogen Inc Logo
Alteogen Inc
KOSDAQ:196170
Watchlist
Price: 356 500 KRW 1.57% Market Closed
Market Cap: 19T KRW
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one Alteogen Inc stock under the Base Case scenario is 88 020.67 KRW. Compared to the current market price of 356 500 KRW, Alteogen Inc is Overvalued by 75%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

Relative Value
Base Case
88 020.67 KRW
Overvaluation 75%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

184.7
P/S
P/S
Price to Sales
184.7
vs History
12
vs Industry
9
Median 3Y
69.8
Median 5Y
75.5
Industry
6.9
Forward
84
More Details
305.2
P/E
P/E
Price to Earnings
305.2
vs History
34
vs Industry
0
Median 3Y
300.5
Median 5Y
219.8
Industry
22.4
Forward
205.1
More Details
358.2
P/OCF
P/OCF
Price to OCF
358.2
vs History
33
vs Industry
0
Median 3Y
-131
Median 5Y
119.6
Industry
19.1
More Details
426.9
P/FCFE
P/FCFE
Price to FCFE
426.9
vs History
12
vs Industry
100
Median 3Y
-32.3
Median 5Y
-35.5
Industry
23.2
More Details
69.4
P/B
P/B
Price to Book Value
69.4
vs History
14
vs Industry
0
Median 3Y
21.9
Median 5Y
20.9
Industry
2.5
More Details
183
EV/S
EV/S
Enterprise Value to Sales
183
vs History
12
vs Industry
7
Median 3Y
66.3
Median 5Y
70.5
Industry
7.5
Forward
83.2
More Details
293.8
EV/GP
EV/GP
Enterprise Value to Gross Profit
293.8
vs History
41
vs Industry
3
Median 3Y
306.3
Median 5Y
216.6
Industry
8.9
More Details
666.3
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
666.3
vs History
11
vs Industry
0
Median 3Y
-144.1
Median 5Y
-124.3
Industry
4
Forward
116.1
More Details
741
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
741
vs History
11
vs Industry
100
Median 3Y
-126.5
Median 5Y
-110.8
Industry
3.7
Forward
139.9
More Details
354.9
EV/OCF
EV/OCF
Enterprise Value to OCF
354.9
vs History
33
vs Industry
0
Median 3Y
-124.4
Median 5Y
112.7
Industry
4.5
More Details
658.3
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
658.3
vs History
4
vs Industry
Median 3Y
-60
Median 5Y
-71.8
Industry
3.4
More Details
87.7
EV/IC
EV/IC
Enterprise Value to IC
87.7
vs History
34
vs Industry
2
Median 3Y
35.4
Median 5Y
75.5
Industry
4.6
More Details

Multiples Across Competitors

Competitors Multiples
Alteogen Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
KR
Alteogen Inc
KOSDAQ:196170
19T KRW 184.7 305.2 666.3 741
FR
Pharnext SCA
OTC:PNEXF
6T USD 35 162 939 -167 124.2 -202 942.1 -200 626.3
US
Abbvie Inc
NYSE:ABBV
346.1B USD 6.1 81.7 16.1 24.3
US
Amgen Inc
NASDAQ:AMGN
150.4B USD 4.5 36.8 15.2 26.9
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
128.5B USD 11.7 -240 26.3 27.5
US
Gilead Sciences Inc
NASDAQ:GILD
128.1B USD 4.5 266.9 10.5 13.2
US
Epizyme Inc
F:EPE
94.1B EUR 2 003.5 -511.2 -556.7 -541.9
AU
CSL Ltd
ASX:CSL
121.7B AUD 5.2 28.6 17.6 22
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
66.2B USD 4.7 15 9.4 10.5
US
Seagen Inc
F:SGT
39.3B EUR 19.3 -59.2 -63.7 -57.5
NL
argenx SE
XBRU:ARGX
35.3B EUR 18.2 47.8 -2 704.2 -1 813.1
P/S Multiple
Revenue Growth P/S to Growth
KR
Alteogen Inc
KOSDAQ:196170
Average P/S: 3 196 836.5
184.7
98%
1.9
FR
Pharnext SCA
OTC:PNEXF
35 162 939
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6.1
7%
0.9
US
Amgen Inc
NASDAQ:AMGN
4.5
4%
1.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
11.7
10%
1.2
US
Gilead Sciences Inc
NASDAQ:GILD
4.5
3%
1.5
US
E
Epizyme Inc
F:EPE
2 003.5
N/A N/A
AU
CSL Ltd
ASX:CSL
5.2
7%
0.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
4.7
6%
0.8
US
S
Seagen Inc
F:SGT
19.3
30%
0.6
NL
argenx SE
XBRU:ARGX
18.2
39%
0.5
P/E Multiple
Earnings Growth PEG
KR
Alteogen Inc
KOSDAQ:196170
Average P/E: 111.7
305.2
135%
2.3
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -167 124.2 N/A N/A
US
Abbvie Inc
NYSE:ABBV
81.7
87%
0.9
US
Amgen Inc
NASDAQ:AMGN
36.8
44%
0.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -240 N/A N/A
US
Gilead Sciences Inc
NASDAQ:GILD
266.9
187%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -511.2 N/A N/A
AU
CSL Ltd
ASX:CSL
28.6
16%
1.8
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
15
10%
1.5
US
S
Seagen Inc
F:SGT
Negative Multiple: -59.2 N/A N/A
NL
argenx SE
XBRU:ARGX
47.8
28%
1.7
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
KR
Alteogen Inc
KOSDAQ:196170
Average EV/EBITDA: 108.8
666.3
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -202 942.1 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.1
14%
1.2
US
Amgen Inc
NASDAQ:AMGN
15.2
17%
0.9
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
26.3
18%
1.5
US
Gilead Sciences Inc
NASDAQ:GILD
10.5
7%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -556.7 N/A N/A
AU
CSL Ltd
ASX:CSL
17.6
11%
1.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
9.4
14%
0.7
US
S
Seagen Inc
F:SGT
Negative Multiple: -63.7 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -2 704.2 N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
KR
Alteogen Inc
KOSDAQ:196170
Average EV/EBIT: 123.6
741
189%
3.9
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -200 626.3 N/A N/A
US
Abbvie Inc
NYSE:ABBV
24.3
29%
0.8
US
Amgen Inc
NASDAQ:AMGN
26.9
31%
0.9
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
27.5
17%
1.6
US
Gilead Sciences Inc
NASDAQ:GILD
13.2
11%
1.2
US
E
Epizyme Inc
F:EPE
Negative Multiple: -541.9 N/A N/A
AU
CSL Ltd
ASX:CSL
22
14%
1.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
10.5
13%
0.8
US
S
Seagen Inc
F:SGT
Negative Multiple: -57.5 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -1 813.1 N/A N/A

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 252,600+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.